Imbruvica lassoes CLL indication

Share this article:

The FDA has expanded the indication for Johnson & Johnson and Pharmacyclics' Imbruvica to include chronic lymphocytic leukemia patients who have a chromosome 17 deletion which is associated with a poor response to standard CLL treatments.

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February. The FDA approved Imbruvica for the rare, aggressive cancer mantle cell lymphoma in November 2013.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.